June 28, 2022
Emmanuel Caeymaex, Executive Vice President, Immunology Solutions, UCB UCB expects to see its immunology franchise account for half of its global revenue in the next few years, driven by its new psoriasis drug Bimzelx (bimekizumab) along with the mainstay Cimzia...read more